Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/CIRCULATIONAHA.116.022187 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial.
Eur Urol
April 2024
Department of Urology, University of Southern California, Los Angeles, CA, USA.
Immune checkpoint inhibitors and timing of administration.
Lancet Oncol
February 2022
Division of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. Electronic address:
Adult Langerhans cell histiocytosis with recurrent vulvar ulcers.
Dermatol Ther
May 2020
Bezmialem Vakif University, Dermatology, Fatih, Istanbul, Turkey.
Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients.
J Geriatr Oncol
May 2020
Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States of America. Electronic address:
Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma.
Eur Urol
July 2018
Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!